Tag: FDA biosimilars
Lot-to-Lot Variability in Biologics and Biosimilars: Why It Matters for Patients and Doctors
Lot-to-lot variability is a natural part of biologic and biosimilar manufacturing. Unlike generics, these drugs aren't identical from batch to batch-but they're still safe and effective. Here's how regulators, labs, and manufacturers manage it.